Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q4 2022 call → NOWe need to determine if management explains the company's business direction by narrating what its counterparties are doing and scaling. The key is whether management's forward account is substantially about the growth/expansion of specific customers, partners, etc., that the company already serves, and that this growth is early and large relative to the company. Let's analyze the transcript. Management discusses their own strategy, product launches, clinical trials, and market conditions. They mention "competitive noise" and "reimbursement uncertainty" as headwinds. They talk about their own sales team, new products, and account growth. They do mention "new accounts" and "more active accounts" but that's general. They also mention "hospital outpatient setting" and "physician office setting" but not specific counterparties' own ramps. They talk about CMS publishing ASPs, but that's a regulatory body, not a customer. They mention "competitive pressure from smaller amniotic players" but that's competition, not counterparties they serve. The question asks: does management narrate what its counterparties are themselves doing and scaling? For example, describing a customer's expansion plans, a partner's rollout, etc. Here, management talks about their own efforts to grow accounts, but not about specific customers' own business trajectories. They mention "new product introductions" and "full commercialization" of PuraPlyMZ, but that's their own product. They also discuss the ReNu clinical trial, but that's their own development. There is no mention of a specific customer, partner, or program that is scaling up and driving the company's volume. The forward guidance is based on their own sales efforts and market conditions. So the answer is NO. Thus, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.